Welcome to DU!
The truly grassroots left-of-center political community where regular people, not algorithms, drive the discussions and set the standards.
Join the community:
Create a free account
Support DU (and get rid of ads!):
Become a Star Member
Latest Breaking News
General Discussion
The DU Lounge
All Forums
Issue Forums
Culture Forums
Alliance Forums
Region Forums
Support Forums
Help & Search
"A Shot in The Wallet" - Drug Discovery & Development magazine: Vol. 12, No. 9, October, 2009
http://www.dddmag.com/articles/2009/12/shot-wallet
A Shot in The Wallet
Mon, 12/07/2009 - 8:35am
Ted Agres, Contributing Editor
<>
The global market for vaccines is projected to more than double from $16 billion in 2007 to $35 billion in 2014, far outpacing growth rates for most other pharmaceuticals, according to Scientia Advisors LLC, a Cambridge-Mass. consulting firm. This builds on a near tripling in sales from 2000 to 2008, according to the World Health Organization’s most recent report on vaccines and immunizations. Most of this expansion came from sales in industrialized countries of newer, more costly vaccines, which account for more than half of the total value of vaccine sales worldwide, WHO said.
<>
So far this year, governments worldwide have ordered nearly 600 million doses of H1N1 vaccine and adjuvants worth $4.3 billion with the potential for adding another 342 million more doses worth $2.6 billion, according to the JPMorgan investment bank. This $7 billion in sales will provide a mini-booster shot for biopharmaceutical manufacturers which, like other big pharmas, are desperate to replace revenues lost to generic competition as blockbuster drugs lose patent protection.
Vaccines also occupy a nicely protected niche. Unlike their small-molecule chemical counterparts, biological drugs cannot be easily produced. At the moment, only six egg-based vaccine production facilities are licensed in the U.S., creating a steep barrier to entry for would-be competitors.
In addition, the FDA does not allow the marketing of “follow-on” or so-called generic biologics in the U.S., although bills to do so are being debated in Congress. And vaccine manufacturers enjoy partial immunity from liability lawsuits through the 1986 National Vaccine Injury Compensation Program, designed to encourage vaccine manufacturing after dozens of companies—hit with numerous and costly lawsuits—got out of the business in the 1970s and 1980s.
<>
About the Author: Contributing editor Ted Agres, MBA, is a veteran science writer in Washington, DC. He writes frequently about the policy, politics, and business aspects of life sciences.
This article was published in Drug Discovery & Development magazine: Vol. 12, No. 9, October, 2009, p. 8.
A Shot in The Wallet
Mon, 12/07/2009 - 8:35am
Ted Agres, Contributing Editor
<>
The global market for vaccines is projected to more than double from $16 billion in 2007 to $35 billion in 2014, far outpacing growth rates for most other pharmaceuticals, according to Scientia Advisors LLC, a Cambridge-Mass. consulting firm. This builds on a near tripling in sales from 2000 to 2008, according to the World Health Organization’s most recent report on vaccines and immunizations. Most of this expansion came from sales in industrialized countries of newer, more costly vaccines, which account for more than half of the total value of vaccine sales worldwide, WHO said.
<>
So far this year, governments worldwide have ordered nearly 600 million doses of H1N1 vaccine and adjuvants worth $4.3 billion with the potential for adding another 342 million more doses worth $2.6 billion, according to the JPMorgan investment bank. This $7 billion in sales will provide a mini-booster shot for biopharmaceutical manufacturers which, like other big pharmas, are desperate to replace revenues lost to generic competition as blockbuster drugs lose patent protection.
Vaccines also occupy a nicely protected niche. Unlike their small-molecule chemical counterparts, biological drugs cannot be easily produced. At the moment, only six egg-based vaccine production facilities are licensed in the U.S., creating a steep barrier to entry for would-be competitors.
In addition, the FDA does not allow the marketing of “follow-on” or so-called generic biologics in the U.S., although bills to do so are being debated in Congress. And vaccine manufacturers enjoy partial immunity from liability lawsuits through the 1986 National Vaccine Injury Compensation Program, designed to encourage vaccine manufacturing after dozens of companies—hit with numerous and costly lawsuits—got out of the business in the 1970s and 1980s.
<>
About the Author: Contributing editor Ted Agres, MBA, is a veteran science writer in Washington, DC. He writes frequently about the policy, politics, and business aspects of life sciences.
This article was published in Drug Discovery & Development magazine: Vol. 12, No. 9, October, 2009, p. 8.
4 replies
= new reply since forum marked as read
= new reply since forum marked as read
http://vaccine-schedule.ecdc.europa.eu
[img]
[/img]
Vaccine Schedule
ECDC collects information on vaccination schedules in the EU/EEA countries with the help of ECDC national focal points. This tool allows for comparison of shedules between two countries and diseases for all or a selection of countries.
<>
[img]
[/img]
Vaccine Schedule
ECDC collects information on vaccination schedules in the EU/EEA countries with the help of ECDC national focal points. This tool allows for comparison of shedules between two countries and diseases for all or a selection of countries.
<>
http://adventuresinautism.blogspot.com/2013/07/welcome-ernest-hancock-listeners.html
By Ginger Taylor
July 2, 2013
CDC recommended childhood vaccine schedule, pre and post 1986 National Childhood Vaccine Injury Act that gave complete liability protection to the vaccine industry, public health and medical professionals:
[center]
[/center]
By Ginger Taylor
July 2, 2013
CDC recommended childhood vaccine schedule, pre and post 1986 National Childhood Vaccine Injury Act that gave complete liability protection to the vaccine industry, public health and medical professionals:
[center]
[/center]Related: http://www.hrsa.gov/vaccinecompensation/index.html
http://www.cdc.gov/vaccines/news/newsltrs/imwrks/2014/2014-01.html
[img]
[/img]
New Director of the Immunization Services Division (ISD), National Center for Immunization and Respiratory Diseases (NCIRD): Dr. Melinda Wharton has been appointed as the new Director of ISD/NCIRD. Dr. Wharton is well known to the immunization community, as she has worked in CDC’s immunization program since 1992 and served as Deputy Director of NCIRD from 2006 to the present. Dr. Wharton is a national and international expert in vaccine policy, vaccine safety science, and public health response. Dr. Wharton has authored or co-authored more than 95 scientific journal articles, book chapters, and CDC publications. She is the recipient of numerous awards, including the Philip R. Horne Award and the HHS Secretary’s Award for Distinguished Service. She currently chairs the Global Advisory Committee on Vaccine Safety for the World Health Organization.
Dr. Wharton graduated from the University of Oklahoma with highest honors and received her medical degree from Harvard Medical School and a master’s in public health from Johns Hopkins School of Hygiene and Public Health. She completed her internship and residency in internal medicine at the University of Michigan Medical Center, in Ann Arbor, Michigan, and her infectious diseases fellowship at the Duke University Medical Center in Durham North Carolina. She joined CDC as an Epidemic Intelligence Service Officer in 1986 and was assigned to the Tennessee Department of Health and Environment in Nashville, Tennessee. In 1989, she began work as a medical epidemiologist in CDC's Epidemiology Program Office.
She joined CDC's immunization program in 1992 and since that time has held a variety of positions of increasing responsibility, including serving as Chief of the Child Vaccine Preventable Diseases Branch from 1994-2000 and as Director of the Epidemiology and Surveillance Division from 2000-2004. Dr. Wharton also served as Acting Director of CDC’s Immunization Safety Office and of the Immunization Services Division during periods of transition in those units. Dr. Wharton brings tremendous expertise and her customary wisdom and calm to complex leadership demands.
2014 Immunization Schedules: Every year, recommendations for routine use of vaccines in children, adolescents, and adults are developed by the Advisory Committee on Immunization Practices (ACIP) and, when adopted by the Director of CDC, become official CDC/HHS policy. In early 2014, MMWR will publish a summary of schedule changes but will not publish the figures, footnotes, and tables. 2014 figures, footnotes, and tables will only be published on the CDC website.
The 2014 child and adolescent schedule is set to be released on January 31 and the adult schedule is set to be released on February 3. Until then, the 2013 schedules will remain on the website.
CDC encourages organizations to content syndicate rather than copy a PDF version of the schedule onto their websites to share with visitors. Content syndication allows other organizations’ websites to mirror CDC web content, with immediate and automatic updates whenever changes are made on the CDC site. This helps ensure that all schedules are current across the Internet.
Recent Internet searches reveal hundreds of old copies of the schedules; please use this best practice to keep your website up to date. Prepare now for the release of the 2014 schedules by following the steps to display the schedules on your site.
More.
[img]
[/img]
New Director of the Immunization Services Division (ISD), National Center for Immunization and Respiratory Diseases (NCIRD): Dr. Melinda Wharton has been appointed as the new Director of ISD/NCIRD. Dr. Wharton is well known to the immunization community, as she has worked in CDC’s immunization program since 1992 and served as Deputy Director of NCIRD from 2006 to the present. Dr. Wharton is a national and international expert in vaccine policy, vaccine safety science, and public health response. Dr. Wharton has authored or co-authored more than 95 scientific journal articles, book chapters, and CDC publications. She is the recipient of numerous awards, including the Philip R. Horne Award and the HHS Secretary’s Award for Distinguished Service. She currently chairs the Global Advisory Committee on Vaccine Safety for the World Health Organization.
Dr. Wharton graduated from the University of Oklahoma with highest honors and received her medical degree from Harvard Medical School and a master’s in public health from Johns Hopkins School of Hygiene and Public Health. She completed her internship and residency in internal medicine at the University of Michigan Medical Center, in Ann Arbor, Michigan, and her infectious diseases fellowship at the Duke University Medical Center in Durham North Carolina. She joined CDC as an Epidemic Intelligence Service Officer in 1986 and was assigned to the Tennessee Department of Health and Environment in Nashville, Tennessee. In 1989, she began work as a medical epidemiologist in CDC's Epidemiology Program Office.
She joined CDC's immunization program in 1992 and since that time has held a variety of positions of increasing responsibility, including serving as Chief of the Child Vaccine Preventable Diseases Branch from 1994-2000 and as Director of the Epidemiology and Surveillance Division from 2000-2004. Dr. Wharton also served as Acting Director of CDC’s Immunization Safety Office and of the Immunization Services Division during periods of transition in those units. Dr. Wharton brings tremendous expertise and her customary wisdom and calm to complex leadership demands.
2014 Immunization Schedules: Every year, recommendations for routine use of vaccines in children, adolescents, and adults are developed by the Advisory Committee on Immunization Practices (ACIP) and, when adopted by the Director of CDC, become official CDC/HHS policy. In early 2014, MMWR will publish a summary of schedule changes but will not publish the figures, footnotes, and tables. 2014 figures, footnotes, and tables will only be published on the CDC website.
The 2014 child and adolescent schedule is set to be released on January 31 and the adult schedule is set to be released on February 3. Until then, the 2013 schedules will remain on the website.
CDC encourages organizations to content syndicate rather than copy a PDF version of the schedule onto their websites to share with visitors. Content syndication allows other organizations’ websites to mirror CDC web content, with immediate and automatic updates whenever changes are made on the CDC site. This helps ensure that all schedules are current across the Internet.
Recent Internet searches reveal hundreds of old copies of the schedules; please use this best practice to keep your website up to date. Prepare now for the release of the 2014 schedules by following the steps to display the schedules on your site.
More.
